Properties (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
multiple companies
|
| gptkbp:awards |
various industry awards
|
| gptkbp:clinicalTrials |
ongoing
collaborative studies patient-centered trials biomarker_studies |
| gptkbp:collaborations |
various pharmaceutical companies
|
| gptkbp:communityInvolvement |
patient support initiatives
supporting cancer research |
| gptkbp:employees |
over 300
|
| gptkbp:financialPerformance |
private company
|
| gptkbp:founded |
1977
|
| gptkbp:founder |
Helsinn_Holding_S.A.
|
| gptkbp:globalPresence |
operates in over 70 countries
|
| gptkbp:headquarters |
gptkb:Lugano,_Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Helsinn Group
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:investmentFocus |
infrastructure development
technology advancements R&D funding |
| gptkbp:mission |
improving patient outcomes
|
| gptkbp:operatesIn |
global market
|
| gptkbp:partnerships |
non-profit organizations
academic institutions various research institutions healthcare_providers |
| gptkbp:productLine |
combination therapies
new formulations multiple candidates in development |
| gptkbp:products |
Helsinn's_antiemetic_products
Helsinn's_oncology_products Palonosetron |
| gptkbp:regulatoryCompliance |
FDA_approved
EMA_approved |
| gptkbp:researchFocus |
oncology
pain management |
| gptkbp:specializesIn |
cancer care
pain management |
| gptkbp:strategicGoals |
foster innovation
improve patient access expand product portfolio enhance global reach |
| gptkbp:subsidiary |
gptkb:Helsinn_Healthcare
Helsinn_Therapeutics |
| gptkbp:sustainability |
social responsibility
ethical practices environmental responsibility |
| gptkbp:values |
gptkb:collaboration
innovation integrity excellence |
| gptkbp:vision |
be a leader in cancer care
|
| gptkbp:website |
www.helsinn.com
|